RecruitingPhase 3NCT06611891

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Sponsor

University Hospital, Grenoble

Enrollment

25 participants

Start Date

Jan 6, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Metastatic

Summary

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 99 Years

Inclusion Criteria9

Age over 18
Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
Patient labeled on the primary lesion ER+HER2- (20)
Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
Person affiliated to or benefiting from social security
Person who has given written informed consent

Exclusion Criteria7

Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
Known allergy to 68Ga-DOTATOC or its excipients
Subject refusing to sign the consent to participate
Minor subject
Subject excluded from another study
Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
Subject cannot be contacted in case of emergency